.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the icon "BIOA," according to documents submitted with the Stocks and Exchange Compensation. The company has actually not openly shared an assumed monetary quantity for the offering.The clinical-stage provider promotes lead prospect azelaprag, an orally provided little molecule slated to enter period 2 testing in combo along with semaglutide-- sold through Novo Nordisk under brand Wegovy for weight-loss-- in the first one-half of upcoming year. Semaglutide is additionally offered as Ozempic and also Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is made to blend well with GLP-1 medications, enhancing weight reduction while keeping muscle mass. The investigational medication was located to become well-tolerated amongst 265 people throughout eight stage 1 trials, depending on to BioAge.Earlier, BioAge gathered the help of Lilly to operate a trial integrating azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetic issues as Mounjaro as well as Zepbound for weight management. The companions are currently administering a phase 2 trial of azelaprag and tirzepatide, with topline results assumed in the 3rd fourth of 2025.The biotech is likewise planning an insulin sensitivity proof-of-concept trial analyzing azelaprag as a monotherapy in the 1st half of next year to sustain prospective indicator development. Furthermore, the provider intends to ask the FDA for consent in the 2nd fifty percent of 2025 to launch individual testing for an NLRP3 inhibitor targeting metabolic illness and also neuroinflammation.BioAge's anticipated relocate to the public market complies with a slight uptick in intended biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the current IPO garden is actually a "blended photo," with high-quality companies still debuting on the general public markets, simply in decreased amounts, depending on to PitchBook.